Abstract 2961: HLA-G-TCB (RG6353), a T cell bispecific antibody for the treatment of solid tumors in monotherapy and combination with immunomodulator agents
Meher Majety(Roche Pharma AG (Germany)), Pablo Umaña(Zurich Insurance Group (Switzerland)), Alexander Bujotzek(Roche Pharma AG (Germany)), Nitya Nair(490 BioTech (United States)), Christian Klein(Roche (Switzerland)), Stefan L. Zimmerman(Johns Hopkins Hospital), Anthony Morel(Roche (Switzerland)), Carina Hage(Roche Pharma AG (Germany)), Anneliese Schneider(Roche (Switzerland)), Martin Lechmann(Roche (Switzerland))
Cited by 0
Related Papers
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
|Journal of Clinical Oncology|2021|428
Computationally guided personalized targeted ablation of persistent atrial fibrillation
|Nature Biomedical Engineering|2019|318